FAPI PET Imaging - An Exploratory Study

Starting soon · Phase 1/Phase 2

Conditions studied: Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis, Thyroid Cancer, Breast Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer (GC), Pancreatic Cancer, Adult, Urothelial Carcinoma (UC), Multiple Myeloma or Plasmacytoma, Mesothelioma, Hepatic Fibrosis, Endometriosis (Diagnosis), Lung Fibrosis, Neck Node Metastasis, Prostate Cancer (CRPC)

In brief

This study is testing a new imaging tracer called \[18F\]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions like fibrosis and sarcoidosis. \[18F\]FAPI-74 attaches to a protein found on cells that are active in tumors and areas of scarring or inflammation. This may help doctors see these areas more clearly than with imaging methods used today, especially in diseases where current scans do not work well. People who join this study will get one injection of the tracer into a vein, then have one PET/CT or PET/MR scan. This takes about 2 hours in total. Researchers will compare the results with imaging the participant already had as part of their regular care, such as other PET scans, CT, or MRI. No extra treatment is given, and no other visits are needed. The study will take place at 5 hospitals in Switzerland and plans to include about 770 adults with a confirmed or suspected diagnosis of one of the conditions being studied. The main goal is to see how clearly the tracer shows up on the scan. Researchers will also look at whether this new scan changes how confident doctors feel about a diagnosis, or changes the patient's treatment plan.

Key facts

Study ID

NCT07705074

Run by

Martin Huellner

People needed

770

Starts

2026-08-01

Expected to finish

2029-09-01

Last updated by the study team

2026-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent obtained and documented by the participant's signature.
• Age ≥18 years at the time of consent.
• Clinically established or suspected diagnosis or recurrence of an oncologic or non-oncologic disease as defined in chapter 7.1 of study protocol.
• Availability of standard-of-care imaging (e.g., clinically established PET tracer or anatomical imaging such as CT/MRI) to allow comparative evaluation.

You may not qualify if…

• Severe claustrophobia that would preclude PET imaging.
• Inability to remain still for the duration of the PET/MR examination.
• Current pregnancy or breastfeeding; no pregnancy test is required for women who are postmenopausal for ≥12 months or have undergone surgical sterilization, bilateral oophorectomy, or hysterectomy.
• Previous hypersensitivity reactions to radiotracer administration
• Inability to understand the study information, for example due to language barriers.
• Subjects incapable of judgment (e.g. individuals under legal or medical incapacity).
• Participants scheduled for PET/MR imaging: Presence of MRI-incompatible metallic implants, electronic devices (e.g. pacemakers, cochlear implants), or other ferromagnetic foreign bodies.

Where it is running

• Kantonsspital Baden — Baden, Canton of Aargau, Switzerland
• Hôpitaux Universitaires de Genève (HUG) — Geneva, Canton of Geneva, Switzerland
• Luzerner Kantonsspital — Lucerne, Canton of Lucerne, Switzerland
• Clinique de Genolier — Genolier, Canton of Vaud, Switzerland
• Department for Nuclear Medicine, University Hospital Zurich — Zurich, Canton of Zurich, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.